The UCI Health Chao Family Comprehensive Cancer Center is now enrolling patients in these featured clinical trials.

To refer a patient or get more information about a clinical trial, click on the principal investigator’s name to send an email. You may also contact us at ucstudy@uci.edu or 877-UC-Study. To search all cancer clinical trials now available at UCI Health, visit cancer.uci.edu/clinical-trials-flowcharts

**Brain and nervous system**

A multicenter, open-label study with a randomized control arm of the efficacy, safety and pharmacokinetics of intravenously infused berubicin in adult patients with recurrent glioblastoma multiforme after failure of standard first-line therapy (UCI-21-18/CNS-201)

*For more information, contact principal investigator Daniela Bota, MD*

A phase 2 study of the PARP inhibitor olaparib (AZD2281) in IDH1- and IDH2-mutant advanced solid tumors (ETCTN-10129)

*For more information, contact principal investigator Xiao-Tang Kong, MD*

**Breast**

A phase 1/2, open-label, dose-escalation study of oral ORIN1001 with and without chemotherapy in the treatment of subjects with solid tumors (UCI-21-82/ORIN1001-001)

*For more information, contact principal investigator Ritesh Parajuli, MD*

A phase 2 trial of radium-223 dichloride in combination with paclitaxel in patients with
metastatic breast cancer that has spread to the bones (ETCTN-10302)
For more information, contact principal investigator Ritesh Parajuli, MD

Gastrointestinal

A phase 2, single-arm study of M6620 in combination with irinotecan in patients with progressive TP53-mutant gastric and gastroesophageal junction cancer (ETCTN-10211)
For more information, contact principal investigator Farshid Dayyani, MD

A phase 1/2, first-in-human study of JTX-8064 as monotherapy and in combination with a PD-1 inhibitor in adult subjects with advanced refractory solid tumors (UCI-20-213/JTX-8064-101)
For more information, contact principal investigator Farshid Dayyani, MD

Genitourinary

An open-label study of androgen receptor inhibition with darolutamide + androgen deprivation therapy (ADT) vs. ADT in men with metastatic hormone-sensitive prostate cancer using an external control arm (ARESEC) (UCI-21-130/21516)
For more information, contact principal investigator Edward Uchio, MD

A randomized phase 2 trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer, where cisplatin-based treatment is not an option (ETCTN-10100)
For more information, contact principal investigator Nataliya Mar, MD

A phase 3, open-label, randomized study evaluating metastatic, castrate-resistant prostate cancer treatment using PSMA [Lu-177]-PNT2002 therapy after second-line hormonal treatment (SPLASH) (UCI-20-181/PBP-301)
For more information, contact principal investigator Arash Rezazadeh Kalebasty, MD

Gynecologic oncology

A prospective phase 2 trial of high-dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: Groningen International study on sentinel nodes in vulvar cancer (GROINSS-V III/NRG-GY024)
For more information, contact principal investigator Krishnansu Tewari, MD

*For more information, contact principal investigator Krishnansu Tewari, MD*

**Head and neck**

Randomized phase 2 and phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) (HN001)

*For more information, contact principal investigator Rupali Nabar, MD*

A randomized phase 2/3 trial of adjuvant radiation therapy with cisplatin + docetaxel-cetuximab or cisplatin-atezolizumab in pathologic, high-risk squamous cell cancer of the head and neck (RTOG-1216)

*For more information, contact principal investigator Rupali Nabar, MD*

**Hematologic malignancies**

A phase 1/2, open-label, multicenter trial to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkins lymphoma or chronic lymphocytic leukemia (UCI-21-19/MB106-CD20-001)

*For more information, contact principal investigator Susan O’Brien, MD*

A phase 1b/2, open-label, multicenter study of the safety and efficacy of TL-895 combined with KRT-232 in subjects with relapsed or refractory FLT3+ acute myeloid leukemia (AML) (UCI-20-177/TL-895-203)

*For more information, contact principal investigator Deepa Jeyakumar, MD*

**Hepatobiliary**

A phase 1/2 study of M3814 (peposertib) in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma (ETCTN-10366)

*For more information, contact principal investigator Farshid Dayyani, MD*

A phase 1b/2, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with advanced liver cancers (Morpheus-Liver) (UCI-20-79/GO42216)

*For more information, contact principal investigator Farshid Dayyani, MD*
Lung

A phase 2 study of nivolumab + relatlimab in combination with chemotherapy vs. nivolumab in combination with chemotherapy as first-line treatment for subjects with stage IV or recurrent non-small cell lung cancer (NSCLC) (UCI-20-158/CA224-104)

For more information, contact principal investigator Sai-Hong Ou, MD

A phase 1/2 study of the highly selective ROS1 inhibitor NUV-520 in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors (UCI-21-47/NVL-520-01)

For more information, contact principal investigator Sai-Hong Ou, MD

Skin

An open-label, multicenter phase 1/2 study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors (IGNYTE) (UCI-18-64/RPL-001-16)

For more information, contact principal investigator John Fruehauf, MD

A phase 2 study of talimogene laherparepvec followed by talimogene laherparepvec and nivolumab in refractory T-cell and NK-cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma and other rare skin tumors (ETCTN-10057)

For more information, contact principal investigator Maki Yamamoto, MD